RxDoctor Payments DataLook up a doctor →

Amy Spizuoco, DO

Dermatology · New York, NYNPI 1285952515

Payments from drug & device makers

$1,286,886in general payments, 2019–2025

Across 2,500 payments — averaging $514.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$205K
  • Sanofi$174K
  • Galderma Laboratories, L.p.$166K
  • Amgen$150K
  • Arcutis Biotherapeutics, Inc.$140K
  • E.r. Squibb & Sons, L.L.C.$107K
  • plus $344K from 37 others
$7,293in research payments, 2019–2025

Across 1 payment — averaging $7293.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

What the payments were for

  • Consulting fees$200,87616%
  • Speaking & faculty fees$930,09372%
  • Travel & lodging$76,0556%
  • Food & beverage$78,5216%
  • Education$6480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,286,886 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$14,902
Medicare patients
49
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab14$50,657

Paid to pharmacies, not to this prescriber.

Other dermatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →